{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:19:57Z","timestamp":1791206397603,"version":"4.1.0"},"reference-count":43,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":1242,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[1998,8]]},"abstract":"<jats:p>Interleukin 6 plays a key role in the pathogenesis of multiple myeloma (MM). Therefore we conducted a phase I dose\u2010escalating study with chimaeric monoclonal anti\u2010IL6 antibodies (cMab) in MM patients resistant to second\u2010line chemotherapy. The cMab (CLB IL6\/8; <jats:italic>K<\/jats:italic><jats:sub>d<\/jats:sub> 6.25\u2003\u00d7\u200310<jats:sup>\u221212<\/jats:sup>\u2003<jats:sc>M<\/jats:sc>) was given in two cycles of 14 daily infusions, starting on day 1 and day 28, repectively, with a daily dose of 5\u2003mg in patients 1\u20133, 10\u2003mg in patients 4\u20136, 20\u2003mg in patients 7\u20139 and 40\u2003mg in patients 10\u201312 (total dose 140\u2003mg, 280\u2003mg, 560\u2003mg and 1120\u2003mg of anti\u2010IL6, respectively). 11\/12 patients had elevated pretreatment IL6 levels.<\/jats:p><jats:p>Except for transient thrombocytopenia in two patients there was no toxicity. There were no changes in haemoglobin levels, granulocyte count, liver enzymes or renal function. No human anti\u2010chimaeric antibodies were induced. This was also reflected in a long half\u2010life time of the cMab (median 17.8\u2003d), resulting in accumulation of the anti\u2010IL6\u2003cMab and high levels of circulating IL6. However, this was in the form of biologically inactive IL6\/cMab complexes and did not result in acceleration of the disease. Although C\u2010reactive protein (CRP) levels were decreased to below detection level in 11\/12 patients, indicating effective IL6 blocking, none of the patients achieved a response according to the standard criteria. We conclude that this chimaeric anti\u2010IL6 Mab has a low toxicity, low immunogenicity and a long <jats:italic>T<\/jats:italic><jats:sub>1\/2<\/jats:sub>. A dose of 40\u2003mg\/d for 14\u2003d can safely be used in future phase II studies.<\/jats:p>","DOI":"10.1046\/j.1365-2141.1998.00835.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T06:03:20Z","timestamp":1047362600000},"page":"783-790","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Chimaeric anti\u2010interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose\u2010escalating study"],"prefix":"10.1111","volume":"102","author":[{"family":"Van Zaanen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Lokhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Aarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Rensink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Warnaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Van Der Lelie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Van Oers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"reference":[{"key":"e_1_2_5_2_2","unstructured":"Aarden L.(1991) Plasmacytomas.Mechanisms of B\u2010cell Neoplasm(ed. by F. Melchens and M. Potter) pp.419433. Editione Roche Basel."},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830171004"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.7.1915.1915"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.8.1602.1602"},{"key":"e_1_2_5_6_2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/blood.V72.2.429.429","article-title":"Decrease in BSF\u20102\/IL\u20106 response in advanced cases of multiple myeloma","volume":"72","author":"Asaoku H.","year":"1988","journal-title":"Blood"},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1182\/blood.V86.8.3151.3151","article-title":"Myeloma cells upregulate IL6 secretion in osteoblastic cells through cell\u2010to\u2010cell contact but downregulate osteocalcin","volume":"86","author":"Barille S.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V86.2.685.bloodjournal862685","article-title":"Biologic effects of anti\u2010interleukin 6 murine monoclonal antibody in advanced multiple myeloma","volume":"86","author":"Bataille R.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","unstructured":"Bataille R. Chappard D. Klein B.(1992) Mechanism of bone lesions. In: \u2018Multiple myeloma\u2019.Hematology\/Oncology Clinics of North America 6 285295.","DOI":"10.1016\/S0889-8588(18)30345-9"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114392"},{"key":"e_1_2_5_11_2","doi-asserted-by":"crossref","first-page":"561","DOI":"10.4049\/jimmunol.145.2.561","article-title":"Structure\u2013function analysis of human IL6: epitope mapping of neutralizing monoclonal antibodies with amino\u2010 and carboxyl\u2010terminal deletion mutants","volume":"145","author":"Brakenhoff J.","year":"1990","journal-title":"Journal of Immunology"},{"key":"e_1_2_5_12_2","doi-asserted-by":"crossref","unstructured":"Durie B.&Salmon S.(1975)A clinical staging system for multiple myeloma.Cancer 36 842854.","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_5_13_2","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.4049\/jimmunol.153.4.1744","article-title":"Identification of two novel regions of human IL\u20106 responsible for receptor binding and signal transduction","volume":"153","author":"Ehlers M.","year":"1994","journal-title":"Journal of Immunology"},{"key":"e_1_2_5_14_2","unstructured":"Foerster J.(1993) Multiple myeloma.Wintrobe's Clinical Hematology 9th edn (ed. by G. Lee Th. Bithell J. Foerster J. Athens and J. Lukens) p.2222. Lea and Febiger Philadelphia."},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2650621"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830220932"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.1.243"},{"key":"e_1_2_5_18_2","first-page":"1049s","article-title":"Anticipating, recognizing and preventing hazards associated with in vivo use of monoclonal antibodies: special considerations related to human anti\u2010mouse antibodies","volume":"50","author":"Hoffman T.","year":"1990","journal-title":"Cancer Research"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.d01-1784.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb05605.x"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/332083a0"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.2.564.564"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.1.1.1"},{"key":"e_1_2_5_24_2","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.V78.5.1198.1198","article-title":"Murine anti\u2010interleukin\u20106 monoclonal antibody therapy for a patient with plasma cell leukemia","volume":"78","author":"Klein B.","year":"1991","journal-title":"Blood"},{"key":"e_1_2_5_25_2","first-page":"193","article-title":"IL6 is the central tumor growth factor in vitro and in vivo in multiple myeloma","volume":"1","author":"Klein B.","year":"1990","journal-title":"European Cytokine Network"},{"key":"e_1_2_5_26_2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood.V73.2.517.517","article-title":"Paracrine rather than autocrine regulation of myeloma cell growth and differentiation by IL6","volume":"73","author":"Klein B.","year":"1989","journal-title":"Blood"},{"key":"e_1_2_5_27_2","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.4049\/jimmunol.144.11.4226","article-title":"IL6 stimulates osteoclast\u2010like multinucleated cell formation in long\u2010term human marrow cultures by inducing IL\u20101 release","volume":"144","author":"Kurihara N.","year":"1990","journal-title":"Journal of Immunology"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830240945"},{"key":"e_1_2_5_29_2","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V84.7.2269.2269","article-title":"Primary tumor cells of myeloma patients induce IL6 secretion in long\u2010term bone marrow cultures","volume":"84","author":"Lokhorst H.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830230846"},{"key":"e_1_2_5_31_2","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.4049\/jimmunol.151.6.3225","article-title":"Antibodies chaperone circulating IL\u20106: paradoxical effects of anti\u2010IL6 \u2018neutralizing\u2019 antibodies in vivo","volume":"151","author":"May L.","year":"1993","journal-title":"Journal of Immunology"},{"key":"e_1_2_5_32_2","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood.V84.6.1887.1887","article-title":"Sustained high levels of circulating chaperoned interleukin\u20106 after active specific cancer immunotherapy","volume":"84","author":"May L.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_5_33_2","first-page":"55","article-title":"Murine anti\u2010human IL6 monoclonal antibody prolongs the half\u2010life time in circulating blood and thus prolongs the bioactivity of human IL6 in mice","volume":"74","author":"Mihara M.","year":"1991","journal-title":"Immunology"},{"key":"e_1_2_5_34_2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/blood.V85.4.917.bloodjournal854917","article-title":"Pharmacokinetic study of IL6 therapy with monoclonal antibodies: enhancement of IL6 clearance by cocktails of anti\u2010IL6 antibodies","volume":"85","author":"Montero\u2010Julian F.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_5_35_2","doi-asserted-by":"crossref","first-page":"813","DOI":"10.4049\/jimmunol.139.3.813","article-title":"Purification and NH2\u2010terminal sequence of a plasmacytoma growth\u2010factor derived from the murine macrophage cell line P 388 D1","volume":"139","author":"Nordan R.","year":"1987","journal-title":"Journal of Immunology"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(95)00179-H"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08086.x"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.6.1467.1467"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.137"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01738469"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118932"},{"key":"e_1_2_5_42_2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V85.3.685.bloodjournal853685","article-title":"Secretion of cytokines (IL\u20101alpha, IL\u20103, IL\u20106 and GM\u2010CSF) by normal human bone marrow megakaryocytes","volume":"85","author":"Wickenhauser C.","year":"1995","journal-title":"Blood"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920315)69:6<1373::AID-CNCR2820690612>3.0.CO;2-1"},{"key":"e_1_2_5_44_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.V74.1.11.11","article-title":"IL6 is a potent myeloma cell growth factor in patients with aggressive MM","volume":"74","author":"Zhang X.G.","year":"1989","journal-title":"Blood"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.1998.00835.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2141.1998.00835.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2141.1998.00835.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T01:53:36Z","timestamp":1698458016000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2141.1998.00835.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,8]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1998,8]]}},"alternative-id":["10.1046\/j.1365-2141.1998.00835.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2141.1998.00835.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,8]]},"assertion":[{"value":"2001-12-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}